Summary
Serotonin (5-hydroxytryptamine, 5-HT) is one of the most consistently implicated neurotransmitter systems in autism. The connection dates to 1961, when Schain and Freedman reported elevated whole-blood serotonin in autistic children, making it one of the earliest biological findings in autism research and one of the most replicated. Six decades later, the serotonin system remains central to autism neuroscience, though no single serotonin-based explanation of autism has been established. The evidence is accumulating from genetics, blood markers, receptor studies, gut-brain signalling, and pharmacological probing, but has not yet converged into a definitive account.
Hyperserotonemia
Elevated whole-blood serotonin (hyperserotonemia) is present in roughly 30% of autistic individuals. This was the first biomarker identified in autism and remains among the most robust. A 2024 systematic review (Bhatt et al.) screened over 1,100 publications and confirmed the finding across 59 studies, while concluding that the causes and behavioural consequences remain unclear.
The complication is that whole-blood serotonin is primarily a measure of serotonin stored in platelets, which is almost entirely derived from the gut rather than the brain. Peripheral and central serotonin systems are largely separate: the blood-brain barrier prevents free exchange. What elevated platelet serotonin tells us about brain serotonin function is therefore indirect at best. It may reflect differences in serotonin transporter (SERT) activity, in gut serotonin production, or in platelet uptake, none of which maps straightforwardly onto brain function.
Genetic associations
Several genes in the serotonin pathway are associated with autism. Polymorphisms in genes for serotonin synthesis (TPH2), the serotonin transporter (SLC6A4/SERT), and serotonin receptors (especially HTR2A, the gene for the 5-HT₂A receptor) appear in various association studies. None is a single causal gene; the associations are probabilistic and of small effect.
The SERT Ala56 variant is particularly well-characterised. Transgenic mice carrying this variant show enhanced serotonin clearance, hyperserotonemia, and 5-HT₁A and 5-HT₂A receptor hypersensitivity, alongside altered social function, communication, and repetitive behaviour. The variant also causes both central nervous system and enteric nervous system abnormalities, linking the gut and brain dimensions of the serotonin story.
The 5-HT₂A receptor
This receptor is of particular interest because it sits at the intersection of several processes relevant to autism.
5-HT₂A is involved in dendritic maturation, neuronal differentiation, and regulation of brain-derived neurotrophic factor (BDNF) during development. Early perturbations in 5-HT₂A signalling may shape subsequent brain architecture. The receptor is densely expressed in sensorimotor integration regions and in the default mode network (DMN), exactly the areas implicated in both sensory processing differences and self-referential processing in autism.
Lower cortical 5-HT₂A receptor binding has been correlated with social communication differences in autism, though the evidence is correlational. The receptor is also the principal (though not exclusive) target of psilocybin and other classic psychedelics, making psilocybin a pharmacological probe for the receptor’s role. The PSILAUT trial (Whelan et al. 2024) is using psilocybin to test whether 5-HT₂A function differs between autistic and non-autistic brains.
The gut-brain connection
About 95% of the body’s serotonin is produced in the gut, synthesised by enterochromaffin cells using tryptophan hydroxylase 1 (TPH1). The gut microbiome influences serotonin production, and differences in gut microbiota composition have been reported in autistic individuals. Whether gut-derived serotonin differences contribute to autism through the gut-brain axis, or whether they are an epiphenomenon of shared upstream processes, is an active research question.
The SERT Ala56 mouse model is suggestive: the same transporter variant causes both gut and brain abnormalities, indicating that serotonin system differences can affect both systems simultaneously through a shared mechanism rather than one causing the other.
The excitation-inhibition balance connection
5-HT₂A receptor signalling increases cortical glutamate and thalamic GABA levels, influencing the balance between excitatory and inhibitory neurotransmission. Excitation-inhibition (E/I) imbalance is independently proposed as a contributor to sensory processing differences in autism. The serotonin system may be one of the upstream regulators of that balance.
The predictive processing connection
Under the predictive processing framework (see Predictive processing and autism), 5-HT₂A receptor function is hypothesised to modulate the precision weighting of priors versus sensory evidence. The REBUS model (Carhart-Harris & Friston, 2019) proposes that 5-HT₂A stimulation reduces the precision of high-level priors, relaxing beliefs. If this receptor functions differently in autistic brains, it could be part of the mechanism by which autistic brains assign different weights to prediction errors.
Open questions
Does the 5-HT₂A pathway function differently in autistic versus non-autistic brains? No study has yet directly tested this; all prior evidence is correlational or genetic. The PSILAUT trial is designed to answer this question.
What about autistic people with intellectual disability? PSILAUT excludes this population for ethical and practical reasons. Whether serotonin system differences apply beyond the adult-without-ID population is unknown.
Is peripheral serotonin elevation causally meaningful, or is it an epiphenomenon of a shared upstream process? The SERT Ala56 model suggests a shared mechanism, but human evidence is limited.
How does 5-HT₂A interact with other serotonin receptors? Psilocin binds at least seven other serotonin receptor subtypes. The specificity of any finding to 5-HT₂A will need careful disentangling.
Implications for practice (tentative)
The serotonin evidence is not yet actionable at the level of daily care. What it does is deepen the understanding of why sensory processing differences occur, moving from “this person’s brain processes stimuli differently” to a possible mechanism involving serotonergic modulation of cortical gain. That deeper understanding does not change the recommendation to build individual stimulus profiles and maintain prikkelbalans, but it strengthens the theoretical grounds for those practices.
Key sources
- Schain, R.J. & Freedman, D.X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. The Journal of Pediatrics, 58(3), 315–320. https://doi.org/10.1016/s0022-3476(61)80261-8
- Veenstra-VanderWeele, J. et al. (2012). Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proceedings of the National Academy of Sciences, 109(14), 5469–5474. https://doi.org/10.1073/pnas.1112345109
- Bhatt, S.A., Joshi, V.B. & Narkhede, S.R. (2024). A systematic review on autism and hyperserotonemia: state-of-the-art, limitations, and future directions. Brain Sciences, 14(5), 481. https://doi.org/10.3390/brainsci14050481
- Carhart-Harris, R.L. & Friston, K.J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160
- Whelan et al. 2024 — PSILAUT — trial protocol testing 5-HT₂A function in autistic brains
- Roseby & Osborn Moar 2025 — predictive processing framework for psychedelics and autism